Core Insights - Company reported a revenue of 7.173 billion yuan for Q1 2025, representing a year-on-year decline of 4.48% [1] - Net profit reached 151 million yuan, showing a significant year-on-year increase of 166.40% [1] Financial Performance - Revenue for Q1 2025: 7.173 billion yuan, down 4.48% year-on-year [1] - Net profit for Q1 2025: 151 million yuan, up 166.40% year-on-year [1]

一、 说明会召开方式及时间 安道麦股份有限公司（以下简称"公司"）2025 年第一季度报告在深圳证券 交易所网站（www.szse.cn）及指定媒体的披露日为 2025 年 4 月 29 日。 证券代码：000553(200553) 证券简称：安道麦 A(B) 公告编号：2025-18 号 为了让广大投资者进一步了解公司 2025 年第一季度的经营情况，公司将于 2025 年 5 月 7 日（星期三）下午 3:00-4:00 举行 2025 年第一季度网上业绩说明 会。 安道麦股份有限公司 二、 会议语言 关于举办 2025 年第一季度网上业绩说明会的公告 本次会议主要以英文进行，配有中文同声传译，投资者可在观看页面点击"中 文"或"English（英文）"频道选择合适的语言。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三、 公司参会人员 公司总裁兼首席执行官 Gaël Hili 先生、首席财务官 Efrat Nagar 女士和董事 会秘书郭治先生将参加说明会。 说明会分为业绩介绍和问答环节。投资者可在 2025 年 5 月 6 日 18:00 前通 过 ...

Market Overview - The Shanghai Composite Index closed at 3299.76 points, above the annual line, with a change of 0.25% [1] - The total trading volume of A-shares reached 1,121.207 billion yuan [1] Stocks Breaking Annual Line - A total of 106 A-shares have broken above the annual line today [1] - Notable stocks with significant deviation rates include: - Youbuxun: 17.49% deviation, closing price at 15.18 yuan, with a daily increase of 20.00% and turnover rate of 6.57% [1] - Fujilai: 14.53% deviation, closing price at 29.09 yuan, with a daily increase of 20.01% and turnover rate of 30.40% [1] - Chongqing Construction: 8.33% deviation, closing price at 3.01 yuan, with a daily increase of 9.85% and turnover rate of 2.93% [1] Additional Stocks with Minor Deviations - Jiangxi Copper, Meirya, and Laimu Co. have just crossed the annual line with smaller deviation rates [1] - Other stocks with notable performance include: - Changjiang Investment: 7.98% deviation, closing price at 8.01 yuan, with a daily increase of 10.03% [1] - Qingtang City: 7.70% deviation, closing price at 3.78 yuan, with a daily increase of 9.88% [1] - Shenchuan A: 7.45% deviation, closing price at 6.75 yuan, with a daily increase of 9.93% [1] Summary of Stocks with Deviation Rates - A detailed table lists various stocks, their daily change percentages, turnover rates, annual line prices, latest prices, and deviation rates, highlighting the performance of stocks like: - Dongjiang Environmental: 3.70% deviation, closing price at 4.28 yuan, with a daily increase of 10.03% [1] - Feinan Resources: 3.56% deviation, closing price at 19.88 yuan, with a daily increase of 3.92% [1] - The table provides a comprehensive view of the market dynamics and stock performances on the day [2]

证券代码：000553（200553） 证券简称：安道麦A(B) 公告编号：2025-17号 1. 本次股东大会未出现否决议案的情形； 2. 本次股东大会未变更以往股东大会通过的决议。 二、会议召开情况 1. 现场会议召开时间：2025 年 4 月 7 日 14:30 开始 6. 网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 4 月 7 日上午 9:15-9:25 和 9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票系统进 行网络投票的具体时间为：2025 年 4 月 7 日 9:15 至 15:00 期间的任意时间。 1 安道麦股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、重要提示 2. 召开地点：北京市朝阳区朝阳公园南路 10 号院 7 号楼 6 层 3. 召开方式：现场表决与网络投票相结合 4. 召集人：公司董事会 5. 主持人：覃衡德 7. 会议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司法》"）、《深 圳证券交易所股票 ...

北京市天元律师事务所 关于安道麦股份有限公司 2024 年度股东大会的法律意见 京天股字(2025) 第 101 号 致:安道麦股份有限公司 安道麦股份有限公司 (以下简称"公司")2024年度股东大会(以下简称"本次 股东大会")采取现场投票与网络投票相结合的方式召开,其中现场会议于 2025 年 4月7日在北京市朝阳区朝阳公园南路10号院7号楼6层召开。北京市天元律师 事务所 (以下简称"本所") 接受公司聘任,指派本所律师参加本次股东大会现场会 议,并根据《中华人民共和国公司法》《中华人民共和国证券法》(以下简称"《证 券法》")、《上市公司股东会规则》(以下简称"《股东会规则》")以及《安道 麦股份有限公司章程》 (以下简称"《公司章程》") 等有关规定,就本次股东大会 的召集、召开程序、出席现场会议人员的资格、召集人资格、会议表决程序及表决 结果等事项出具本法律意见。 为出具本法律意见,本所律师审查了《安道麦股份有限公司第十届董事会第 十次会议决议公告》《安道麦股份有限公司第十届监事会第四次会议决议公告》《安 道麦股份有限公司 2024 年度股东大会会议通知》 (以下简称"《股东大会通知》") 以及 ...

证券代码：000553（200553） 证券简称：安道麦A(B) 公告编号：2025-16号 5. 对上市公司损益产生的影响：公司将根据企业会计准则的相关规定进行财务 处理，具体处理结果以及对公司本期及期后利润产生的影响，以会计师事务所最终 审计结果为准，预计不会对公司损益产生重大影响。 二、本次仲裁事项的基本情况 安道麦股份有限公司 关于控股子公司所涉业绩承诺 相关仲裁事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、特别提示 1. 案件所处的仲裁阶段：上海国际经济贸易仲裁委员会（上海国际仲裁中心） （以下简称"上海贸仲"）已作出裁决； 2. 上市公司所处的当事人地位：申请人； 3. 涉案的金额：申请人请求支付价格调整支付款项人民币 64,535,827 元、相应 损失赔偿金及律师费、仲裁费等申请人为提起仲裁而支出的全部费用； 4. 裁决支持金额：根据上海贸仲裁决结果，被申请人应向申请人支付价格调整 款项人民币 45,000,000 元、相应损失赔偿金及一定比例的律师费、仲裁费等申请人 为提起仲裁而支出的费用； 特此公告。 1 因安道麦股份 ...

编号：2025-02 | | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | 活动类别 | □现场参观 | | | □其他 （投行会议） | | 参与单位名称及 | 银河证券、诚通证券、广发证券、国金证券、申万宏源证券、华福证券、北京 | | | 宏信资本、中财融商资管、国泽基金、国中长城资管、偕沣资产、三和宏信投 | | 人员姓名 | 资管理有限公司、陕西科技创业投资管理有限公司、盛世国际集团、金泰证券 | | | 投资、中众国际咨询集团有限公司 | | 时间 | 2025 年 3 月 26 日上午 | | 地点 | 公司办公室，北京 | | 上市公司 | 董事会秘书郭治、证券事务代表王竺君 | | 接待人员姓名 | | | | 公司首先介绍了整体业务情况和正在实施的"奋进"战略计划、2024 年 | | | 第四季度和全年业绩，随后回答了投资者关心的问题，主要问题如下： | | | 1. 公司在全球开展经营业务，是如何应对汇率风险的？ | | | 回复：公司在全球数十个市场有销售业务，在很多市场的业务 ...

Group 1: Financial Performance - In 2024, the company achieved a sales structure improvement contributing $53 million for the year and $17 million in Q4 [2] - The overall sales revenue for 2024 showed a year-on-year decline, but the decline in the overall plant protection market was similar, indicating no loss of market share for the company [2] - The company's EBITDA and profit margins improved year-on-year, with Q4 sales showing a 2% increase when excluding currency effects [3] Group 2: Product Development and Market Strategy - The new product introduction rate for 2023 and 2024 was 22%, with no improvement in 2024, reflecting challenges in differentiated product sales [1] - The company is committed to launching new products and enhancing its sales team's capabilities to focus on high-value products [2] - The company strategically decided to reduce focus on volatile-priced products, opting instead for value-innovative products [3] Group 3: Regional Sales Insights - North America was the only region to show year-on-year growth in agricultural business despite a shrinking market size [2] - The company maintains a cautious approach to selling bulk plant protection products, focusing on those that contribute positively to overall profitability [3] Group 4: Cost Management and Operational Efficiency - The "Advancement" plan aims to optimize financial health and reduce costs, although it has led to increased sales and management expenses due to restructuring costs [4] - The company reported a $68 million reduction in operating expenses when excluding special items related to the "Advancement" plan [4] Group 5: Market Challenges and Opportunities - The potential impact of U.S. tariffs on the supply chain is uncertain, but the company believes its diversified production locations mitigate risks [5] - The "One Certificate, One Product" policy is expected to benefit the company's formulation products, although the price outlook remains under pressure [6]

Financial Data and Key Metrics Changes - In Q4 2024, gross profit increased by 14% and EBITDA rose by 45% compared to the same period last year [10][11] - Full year EBITDA for 2024 was 15% higher than 2023, marking one of the few companies in the industry to show growth in EBITDA [10][11] - Sales for Q4 2024 decreased by 2% to $1.1 billion, but at constant exchange rates (CER), they increased by 2% [15] - Full year sales declined by 11% to $4.1 billion, with an 8% decrease in CER [17][19] - The company achieved a gross margin of 25.6% in 2024, up from 22.7% in 2023 [18][19] Business Line Data and Key Metrics Changes - The company experienced a significant improvement in gross profit and EBITDA margins due to better cost management and a favorable product mix [15][19] - The sales volume remained stable, but pricing pressures led to an overall decline in sales [17][19] Market Data and Key Metrics Changes - In North America, the company saw a growth in sales despite a declining market, attributed to strategic deals with major distributors [68][69] - Latin America experienced a 4% increase in local currency sales, but an 8% decline in dollar terms due to currency impacts [22][26] - Asia Pacific saw a decline of 6-7% in sales, influenced by strategic decisions to align sales closer to the agricultural season [22][23] Company Strategy and Development Direction - The company is focused on a "Fight Forward" transformation plan aimed at improving financial health and operational efficiency [34][36] - The strategy includes centralizing corporate functions, optimizing geographical presence, and focusing on high-value products while exiting low-profit markets [41][42][43] - The company aims to enhance its competitive position in the value innovation segment, targeting growers seeking innovation at acceptable prices [47][48] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing pressure on grower profitability and overcapacity in the market, particularly from Chinese producers [7][8] - Despite challenges, the company is optimistic about maintaining momentum into 2025, supported by improved performance metrics in Q4 2024 [75] - The management emphasized the importance of strategic decisions to walk away from low-profit products to focus on value innovation [72][73] Other Important Information - The company reduced its inventory significantly, from $2.4 billion at the end of 2022 to $1.05 billion in 2024, reflecting efficient inventory management [32] - Operating cash flow improved to $528 million, with free cash flow reaching $364 million, higher than the previous year [30][31] Q&A Session Summary Question: Recent price trends of pesticides and market demand - Management indicated that while some active ingredients have seen price increases, the majority remain at historical lows due to overproduction [60][63] Question: Stability of NPI rate and performance of differentiated products - The stable NPI rate reflects ongoing R&D investment, with improvements in sales of differentiated products noted in Q4 [64][65][66] Question: Regional sales performance and North America outlook - Management clarified that while overall sales declined, North America saw growth due to strategic partnerships, maintaining market share [68][69] Question: Impact of Bayer's potential withdrawal from glyphosate market - Management refrained from commenting on competitors but reiterated their strategic focus on high-value products [72] Question: Potential rebound in sales and profits for 2025 - Management did not provide specific guidance but expressed optimism based on Q4 performance improvements [75] Question: Effectiveness of the Fight Forward plan amid rising expenses - Management explained that increased expenses are due to one-time costs related to restructuring and transformation initiatives [76][77] Question: Future business outlook amid U.S. tariff increases - Management acknowledged the challenges posed by tariffs but emphasized the company's diversified production footprint as a mitigating factor [78][84] Question: Implementation of the one product or one registration policy in China - Management is preparing for the policy's implementation, expecting opportunities for growth through differentiated product innovation [86][87] Question: Guidance on short and mid-term targets for expense reduction - Management reiterated that they do not provide guidance but are focused on optimizing operational costs [88] Question: Status of management structure adjustments - Management confirmed that the transformation process is ongoing, with a focus on enhancing competitive strategies and KPIs [89][90]

Core Viewpoint - The company reported a significant decline in revenue and an increase in net losses for the year 2024, indicating ongoing challenges in its financial performance [2]. Financial Performance - In 2024, the company achieved revenue of 29.488 billion yuan, a year-on-year decrease of 10.04% - The net profit attributable to shareholders was -2.903 billion yuan, with a year-on-year loss increase of 80.79% - The net profit after deducting non-recurring gains and losses was -3.025 billion yuan, reflecting a year-on-year loss increase of 63.37% - In Q4 2024, the company recorded revenue of 7.965 billion yuan, a year-on-year decrease of 1.90% but a quarter-on-quarter increase of 20.44% - The net profit attributable to shareholders for Q4 was -1.065 billion yuan, with a year-on-year loss increase of 89.04% and a quarter-on-quarter loss increase of 12.92% [2]. Operational Insights - The company sold 644,000 tons of plant protection products in 2024, a slight year-on-year decrease of 1.3%, with an average price drop of 9.5% - Sales of fine chemical products reached 1.429 million tons, a year-on-year decrease of 8.5%, while the average price increased by 6.2% - Regionally, sales in EAME, Latin America, and Asia-Pacific markets declined by 8.1%, 19.2%, and 12.3% respectively, while North America saw a sales increase of 5.0% [3]. Profitability and Cash Flow - The company's gross margin improved by 2.1 percentage points to 22.9% in 2024, attributed to the depletion of high-cost raw material inventory and improved product mix quality - Operating cash flow net amount increased by 43.7% year-on-year to 3.76 billion yuan - The increase in sales, management, R&D, and financial expense ratios was due to the implementation of the "Advancement" plan, which incurred additional restructuring costs - The company recognized asset impairment losses of 961 million yuan and credit impairment losses of 99.71 million yuan, which pressured overall performance [3]. Product Development - The company is focusing on "value innovation" in niche markets to enhance agricultural productivity by improving the value of non-patented raw materials through proprietary formulation technologies - In 2024, the new product introduction rate reached 22%, indicating a strong contribution from products launched between 2020 and 2024 - New products such as Forpido?, Edaptis?, and Matos? were launched in overseas markets, alongside the expansion of the Asorbital? formulation technology for certain products [4].